Literature DB >> 8413311

Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site.

L C Dorssers1, T van Agthoven, A Dekker, T L van Agthoven, E M Kok.   

Abstract

Duration of response to antiestrogen therapy in metastatic breast cancer is limited due to the development of antiestrogen-resistant tumors. The mechanisms involved are not understood but could originate from (epi)genetic alterations within the tumor cells. We have applied in vitro random insertional mutagenesis with replication defective retroviruses to identify those genes playing a key role in development of antiestrogen resistance in human breast cancer cells. Eighty antiestrogen-resistant cell clones were isolated from 7 x 10(8) estrogen-dependent ZR-75-1 cells, mass-infected with defective retroviruses and subjected to 4-OH-tamoxifen selection. Integration site-specific DNA probes were made by inverse polymerase chain reaction techniques and used to search for common integration sites. Six cell clones were identified with retroviral genome integrations in the same orientation in a single locus, designated breast cancer antiestrogen resistance locus-1 (bcar-1). These bcar-1 cell clones had lost estrogen receptor expression and had become estrogen independent. Our results strongly suggest that alteration of the bcar-1 locus is responsible for development of antiestrogen resistance in human breast cancer cells in vitro. In addition, we have shown that in vitro insertional mutagenesis using defective retroviruses can be applied for gene tagging in human cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413311     DOI: 10.1210/mend.7.7.8413311

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  24 in total

Review 1.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

2.  Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.

Authors:  Sandipan Chakraborty; Pradip Kumar Biswas
Journal:  J Mol Model       Date:  2014-07-25       Impact factor: 1.810

3.  Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.

Authors:  T van Agthoven; T L van Agthoven; A Dekker; P J van der Spek; L Vreede; L C Dorssers
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

4.  Regulation of p130(Cas)/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2.

Authors:  Joerg Kumbrink; Kathrin H Kirsch
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

Review 5.  Tamoxifen resistance in breast cancer: elucidating mechanisms.

Authors:  L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

7.  NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer.

Authors:  Yann Wallez; Peter D Mace; Elena B Pasquale; Stefan J Riedl
Journal:  Genes Cancer       Date:  2012-05

8.  Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton.

Authors:  Michael S Guerrero; J Thomas Parsons; Amy H Bouton
Journal:  Genes Cancer       Date:  2012-05

9.  Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.

Authors:  M F E Godinho; A M Sieuwerts; M P Look; D Meijer; J A Foekens; L C J Dorssers; T van Agthoven
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

10.  CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.

Authors:  T van Agthoven; A M Sieuwerts; J Veldscholte; M E Meijer-van Gelder; M Smid; A Brinkman; A T den Dekker; I M Leroy; W F J van Ijcken; S Sleijfer; J A Foekens; L C J Dorssers
Journal:  Br J Cancer       Date:  2009-11-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.